IPHYF
Price:
$1.65
Market Cap:
$145.93M
Innate Pharma S.A., a biotechnology firm based in Marseille, France, operates globally, focusing on the discovery, advancement, and commercialization of innovative antibody-based therapies, primarily targeting various oncological conditions. The company's clinical pipeline includes several promising candidates: Lacutamab (IPH4102): An anti-KIR3DL2 antibody currently undergoing Phase II clinical evaluation for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor that has progressed to Phase III clinical trials, being investigated for its potential in treating advanced solid tumors, notably colorectal, lung, and hea...[Read more]
Industry
Biotechnology
IPO Date
2015-06-09
Stock Exchange
OTC
Ticker
IPHYF
According to Innate Pharma S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -2.58. This represents a change of 96.90% compared to the average of -1.31 of the last 4 quarters.
The mean historical PE Ratio of Innate Pharma S.A. over the last ten years is 14.27. The current -2.58 PE Ratio has changed -1907.80% with respect to the historical average. Over the past ten years (40 quarters), IPHYF's PE Ratio was at its highest in in the December 2015 quarter at 178.68. The PE Ratio was at its lowest in in the December 2013 quarter at -85.87.
Average
14.27
Median
-3.37
Minimum
-21.09
Maximum
143.33
Discovering the peaks and valleys of Innate Pharma S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 511.23%
Maximum Annual PE Ratio = 143.33
Minimum Annual Increase = -2746.04%
Minimum Annual PE Ratio = -21.09
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -2.91 | 22.39% |
| 2024 | -2.38 | -88.73% |
| 2023 | -21.09 | 511.23% |
| 2022 | -3.45 | -32.77% |
| 2021 | -5.13 | 55.67% |
| 2020 | -3.30 | -82.84% |
| 2019 | -19.21 | -113.40% |
| 2018 | 143.33 | -2746.04% |
| 2017 | -5.42 | -108.70% |
| 2016 | 62.26 | -158.87% |
The current PE Ratio of Innate Pharma S.A. (IPHYF) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-8.79
5-year avg
-6.99
10-year avg
14.27
Innate Pharma S.A.’s PE Ratio is less than Botanix Pharmaceuticals Limited (-0.51), greater than NDT Pharmaceuticals Inc. (-3395.40), less than Molecular Partners AG (-2.02), greater than Scancell Holdings plc (-38.59), greater than Brii Biosciences Limited (-2.80), less than Ascend Wellness Holdings, Inc. (-0.84), less than JW (Cayman) Therapeutics Co. Ltd (-1.04), greater than Hofseth BioCare ASA (-3.84), greater than Kintor Pharmaceutical Limited (-4.64), less than Venus Medtech (Hangzhou) Inc. (-1.27),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.51 | $48.06M | |
| -3395.40 | $84.22M | |
| -2.02 | $181.93M | |
| -38.59 | $286.61M | |
| -2.80 | $107.82M | |
| -0.84 | $107.98M | |
| -1.04 | $98.91M | |
| -3.84 | $65.82M | |
| -4.64 | $160.37M | |
| -1.27 | $186.06M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innate Pharma S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Innate Pharma S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Innate Pharma S.A.'s PE Ratio?
How is the PE Ratio calculated for Innate Pharma S.A. (IPHYF)?
What is the highest PE Ratio for Innate Pharma S.A. (IPHYF)?
What is the 3-year average PE Ratio for Innate Pharma S.A. (IPHYF)?
What is the 5-year average PE Ratio for Innate Pharma S.A. (IPHYF)?
How does the current PE Ratio for Innate Pharma S.A. (IPHYF) compare to its historical average?